Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Adam Denley"'
Supplementary Data from Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f1c5bec188fd923df4d8702e974dc9
https://doi.org/10.1158/1541-7786.22519357
https://doi.org/10.1158/1541-7786.22519357
Publikováno v:
Molecular Cancer Research. 7:1132-1138
Phosphatidylinositol 3-kinases (PI3K) are divided into three classes, which differ in their substrates and products. Class I generates the inositol phospholipids PI(3)P, PI(3,4)P2, and PI(3,4,5)P3 referred as PIP, PIP2, and PIP3, respectively. Class
Autor:
J. Brown, Adam Denley, Robert Esnouf, Briony E. Forbes, John C. Wallace, E Y Jones, Philippe Roche
Publikováno v:
Proteins: Structure, Function, and Bioinformatics. 64:758-768
Insulin-like growth factors (IGFs) are key regulators of cell proliferation, differentiation, and transformation, and are thus pivotal in cancer, especially breast, prostate, and colon neoplasm. Their potent mitogenic and anti-apoptotic actions depen
Publikováno v:
Cytokine & Growth Factor Reviews. 16:421-439
The insulin-like growth factor (IGF) system is a complex network of two soluble ligands; several cell surface transmembrane receptors and six soluble high-affinity binding-proteins. The IGF system is essential for normal embryonic and postnatal growt
Autor:
Jian-Wen Chen, Jan M. Wit, H.A. van Duyvenvoorde, J. A. P. M. de Laat, Alberto M. Pereira, S. W. van Thiel, C. A. Sluimers, J. van Doorn, Johannes A. Romijn, Jeroen J. Bax, Adam Denley, Briony E. Forbes, Marcel Karperien, Yvonne Hilhorst-Hofstee, M.J.E. Walenkamp, M. B Breuning, Subburaman Mohan
Publikováno v:
Journal of clinical endocrinology and metabolism, 90(5), 2855-2864. The Endocrine Society
IGF-I is a key factor in intrauterine development and postnatal growth and metabolism. The secretion of IGF-I in utero is not dependent on GH, whereas in childhood and adult life, IGF-I secretion seems to be mainly controlled by GH, as revealed from
Autor:
Sohye Kang, Peter K. Vogt, Li Zhao, Andreas G. Bader, Jonathan R. Hart, Hao Jiang, Marco Gymnopoulos, Adam Denley
Publikováno v:
Current Topics in Microbiology and Immunology ISBN: 9783642148156
The catalytic and regulatory subunits of class I phosphoinositide 3-kinase (PI3K) have oncogenic potential. The catalytic subunit p110α and the regulatory subunit p85 undergo cancer-specific gain-of-function mutations that lead to enhanced enzymatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a82badaf145f2ac828935909309a7e0
https://doi.org/10.1007/82_2010_80
https://doi.org/10.1007/82_2010_80
Publikováno v:
Methods in enzymology. 438
Signaling by class I phosphatidylinositol 3-kinase (PI3K) controls cell growth, replication, motility, and metabolism. The PI3K pathway commonly shows gain of function in cancer. Two small GTPases, Rheb (Ras homolog enriched in brain) and Ras (rat sa
Autor:
Christian Siebold, Oliver Zaccheo, Gijs I. van Boxel, A. Bassim Hassan, Adam Denley, Robert J.C. Gilbert, Carlie Delaine, E. Yvonne Jones, Briony E. Forbes, James Brown, John C. Wallace
Publikováno v:
The EMBO journal. 27(1)
Embryonic development and normal growth require exquisite control of insulin-like growth factors (IGFs). In mammals the extracellular region of the cation-independent mannose-6-phosphate receptor has gained an IGF-II-binding function and is termed ty
Signaling by class I phosphatidylinositol 3‐kinase (PI3K) controls cell growth, replication, motility, and metabolism. The PI3K pathway commonly shows gain of function in cancer. Two small GTPases, Rheb (Ras homolog enriched in brain) and Ras (rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f140c77ad2b83dfc265369c513304353
https://doi.org/10.1016/s0076-6879(07)38020-8
https://doi.org/10.1016/s0076-6879(07)38020-8
Publikováno v:
Oncogene. 27(18)
The catalytic subunits of class I PI3Ks comprise four isoforms: p110alpha, p110beta, p110delta and p110gamma. Cancer-specific gain-of-function mutations in p110alpha have been identified in various malignancies. Cancer-specific mutations in the non-a